by NIH/National Institute of Allergy and Infectious Diseases MERS-CoV particles on camel epithelial cells. Credit: NIAID and Colorado State University A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to...
